ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

plozasiran

Also written as “Plozasiran Injection”, “ARO-APOC3” and “Plozasiran”.

Its studies are mostly in Hypertriglyceridemia · Dyslipidemias · Hyperlipoproteinemia Type I, led by 2 companies.

Drug pagePlozasiran: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 11, 202112 company-led studies, 2 open or runningNext primary completion: Jul 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arrowhead Pharmaceuticals102 open or runningphase 3since Oct 11, 2021Dec 19, 2018Jul 2028phase 3 · NCT06822790
Visirna Therapeutics HKits history only20 open or runningphase 3since May 31, 2023Feb 14, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Arrowhead Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2018First study: phase 1 study in HypertriglyceridemiaFirst studyNCT03783377 · 112 enrolled · Australia, Canada, New Zealand
  2. Jan 19, 2021Phase 2 study in HypertriglyceridemiaNCT04720534 · 229 enrolled · United States, Australia, Canada and more
  3. Aug 3, 2021Phase 2 study in Mixed DyslipidemiaNCT04998201 · 353 enrolled · United States, Australia, Canada and more
  4. Oct 11, 2021Phase 3 study in Hyperlipoproteinemia Type INCT05089084 · 75 enrolled · United States, Argentina, Australia and more
  5. Jun 7, 2022Phase 2 study in DyslipidemiasNCT05413135 · 418 enrolled · United States, Australia, Canada and more
  6. Feb 29, 2024Named plozasiranINNProposed as its International Nonproprietary Name in WHO's List 130
  7. Mar 29, 20243 phase 3 studies in HypertriglyceridemiaNCT06347133, NCT06347016, NCT06347003
  8. Feb 7, 2025Phase 3 study in HypertriglyceridemiaNCT06822790 · 710 enrolled · United States, Argentina, Australia and more
  9. Mar 12, 2025Phase 3 study in HypertriglyceridemiaNCT06880770 · 288 planned · United States, Argentina, Austria and more

Ahead

  1. Jul 2028Primary completion: phase 3 study in HypertriglyceridemiaNCT06822790
  2. Mar 2029Primary completion: phase 3 study in HypertriglyceridemiaNCT06880770

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 Arrowhead Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06880770Hypertriglyceridemia · United States, Argentina, Austria and more3RecruitingMar 2029288
NCT06822790Hypertriglyceridemia · United States, Argentina, Australia and more3Active, not recruitingJul 2028710
NCT06347133Hypertriglyceridemia · United States, Argentina, Australia and more3CompletedJun 1, 20261,456
NCT06347016Hypertriglyceridemia · United States, Argentina, Brazil and more3CompletedJun 17, 2026311
NCT06347003Hypertriglyceridemia · United States, Argentina, Australia and more3CompletedJun 12, 2026446
NCT05413135Dyslipidemias · United States, Australia, Canada and more2CompletedSep 22, 2025418
NCT05089084Hyperlipoproteinemia Type I · United States, Argentina, Australia and more3CompletedApr 29, 202475
NCT04998201Mixed Dyslipidemia · United States, Australia, Canada and more2CompletedFeb 10, 2023353
NCT04720534Hypertriglyceridemia · United States, Australia, Canada and more2CompletedMar 9, 2023229
NCT03783377Hypertriglyceridemia · Australia, Canada, New Zealand1CompletedFeb 11, 2021112

How it is read

Names in the registry

  • “Plozasiran Injection”, 4 entries
  • “ARO-APOC3”, 4 entries
  • “Plozasiran”, 3 entries
  • “VSA001 injection”, 1 entry

Codes read as this program: VSA001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.